Christopher Haqq, EVP, R&D & Chief Scientific Of at Atara Biotherapeutics, Inc. (ATRA), sold 775 shares at $37.54 ($29K) on 2018-08-15, disclosed to the SEC on 2018-08-16.
Scheduled sale ($29k) by EVP, R&D & Chief Scientific Of under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ATRA | SELL | 2019-02-08 | $956K | — | Filing → |
| ATRA | SELL | 2018-11-15 | $26K | — | Filing → |
| ATRA | SELL | 2018-09-27 | $582K | — | Filing → |